BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 36401978)

  • 1. Exosomal long noncoding RNAs MAGI2-AS3 and CCDC144NL-AS1 in oral squamous cell carcinoma development via the PI3K-AKT-mTOR signaling pathway.
    Li C; Guo H; Xiong J; Feng B; Zhu P; Jiang W; Jiang P; Su X; Huang X
    Pathol Res Pract; 2022 Dec; 240():154219. PubMed ID: 36401978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LncRNA FOXD2-AS1 promotes the growth, invasion and migration of OSCC cells by regulating the MiR-185-5p/PLOD1/Akt/mTOR pathway.
    Liu J; Zhang Y; Wu J; Liu X; Li L; Zhang J
    Cancer Genet; 2024 Jun; 284-285():48-57. PubMed ID: 38729078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypermethylation-Mediated lncRNA MAGI2-AS3 Downregulation Facilitates Malignant Progression of Laryngeal Squamous Cell Carcinoma via Interacting With SPT6.
    Wang J; Yang C; Cao H; Yang J; Meng W; Yu M; Yu L; Wang B
    Cell Transplant; 2023; 32():9636897231154574. PubMed ID: 36852700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long Noncoding RNA LEMD1-AS1 Increases LEMD1 Expression and Activates PI3K-AKT Pathway to Promote Metastasis in Oral Squamous Cell Carcinoma.
    Li Z; Wang J; Wu J; Li N; Jiang C
    Biomed Res Int; 2022; 2022():3543948. PubMed ID: 35983249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Roles of lncRNA MAGI2-AS3 in human cancers.
    Kai-Xin L; Cheng C; Rui L; Zheng-Wei S; Wen-Wen T; Peng X
    Biomed Pharmacother; 2021 Sep; 141():111812. PubMed ID: 34126355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LncRNA MAGI2-AS3 inhibites tumor progression by up-regulating STAM via interacting with miR-142-3p in clear cell renal cell carcinoma.
    Yang R; Chen Z; Ao S; Liang L; Chen Z; Duan X; Zeng G; Deng T
    Cell Signal; 2024 Jan; 113():110954. PubMed ID: 38084836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the expression level of some coding and non-coding genes in oral squamous cell carcinoma.
    Ajorlou M; Bina-Jourshari P; Mirzaei S; Maghsoudloo M; Hashemi M; Mousavi-Niri N; Entezari M
    Mol Cell Probes; 2023 Aug; 70():101916. PubMed ID: 37355145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LncRNA TP73-AS1 Promotes Cell Proliferation and Inhibits Cell Apoptosis in Clear Cell Renal Cell Carcinoma Through Repressing KISS1 Expression and Inactivation of PI3K/Akt/mTOR Signaling Pathway.
    Liu G; Zhao X; Zhou J; Cheng X; Ye Z; Ji Z
    Cell Physiol Biochem; 2018; 48(1):371-384. PubMed ID: 30016766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. YBX1/lncRNA SBF2-AS1 interaction regulates proliferation and tamoxifen sensitivity via PI3K/AKT/MTOR signaling in breast cancer cells.
    Hussain SA; Venkatesh T
    Mol Biol Rep; 2023 Apr; 50(4):3413-3428. PubMed ID: 36754932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long noncoding RNA TFAP2A-AS1 promotes oral squamous cell carcinoma cell growth and movement via competitively binding miR-1297 and regulating TFAP2A expression.
    Yang K; Niu Y; Cui Z; Jin L; Peng S; Dong Z
    Mol Carcinog; 2022 Sep; 61(9):865-875. PubMed ID: 35730908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LncRNA MAGI2-AS3-Encoded Polypeptide Restrains the Proliferation and Migration of Breast Cancer Cells.
    Zhang Z; Yi Y; Wang Z; Zhang H; Zhao Y; He R; Luo Y; Cui Z
    Mol Biotechnol; 2024 Jun; 66(6):1409-1423. PubMed ID: 37358745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long noncoding RNA HAS2-AS1 mediates hypoxia-induced invasiveness of oral squamous cell carcinoma.
    Zhu G; Wang S; Chen J; Wang Z; Liang X; Wang X; Jiang J; Lang J; Li L
    Mol Carcinog; 2017 Oct; 56(10):2210-2222. PubMed ID: 28485478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased expression of lncRNA FTH1P3 promotes oral squamous cell carcinoma cells migration and invasion by enhancing PI3K/Akt/GSK3b/ Wnt/β-catenin signaling.
    Liu M; Gao X; Liu CL
    Eur Rev Med Pharmacol Sci; 2018 Dec; 22(23):8306-8314. PubMed ID: 30556871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MAGI2-AS3 and miR-374b-5p as Putative Regulators of Multiple Sclerosis via Modulating the PTEN/AKT/IRF-3/IFN-β Axis: New Clinical Insights.
    Kortam MA; Elfar N; Shaker OG; El-Boghdady NA; Abd-Elmawla MA
    ACS Chem Neurosci; 2023 Mar; 14(6):1107-1118. PubMed ID: 36878000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long non-coding RNA SLC16A1-AS1: its multiple tumorigenesis features and regulatory role in cell cycle in oral squamous cell carcinoma.
    Feng H; Zhang X; Lai W; Wang J
    Cell Cycle; 2020 Jul; 19(13):1641-1653. PubMed ID: 32450050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LncRNA MAGI2-AS3 inhibits bladder cancer progression by targeting the miR-31-5p/TNS1 axis.
    Tang C; Cai Y; Jiang H; Lv Z; Yang C; Xu H; Li Z; Li Y
    Aging (Albany NY); 2020 Nov; 12(24):25547-25563. PubMed ID: 33231563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long non-coding RNAs PTENP1, GNG12-AS1, MAGI2-AS3 and MEG3 as tumor suppressors in breast cancer and their associations with clinicopathological parameters.
    Záveský L; Jandáková E; Weinberger V; Minář L; Kohoutová M; Slanař O
    Cancer Biomark; 2024; 40(1):61-78. PubMed ID: 38277283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. lncRNA MAGI2-AS3 suppresses castration-resistant prostate cancer proliferation and migration via the miR-106a-5p/RAB31 axis.
    Yang G; Li T; Liu J; Quan Z; Liu M; Guo Y; Wu Y; Ou L; Wu X; Zheng Y
    Genomics; 2023 Mar; 115(2):110599. PubMed ID: 36889366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LAMC2 regulates proliferation, migration, and invasion mediated by the Pl3K/AKT/mTOR pathway in oral.
    Shan F; Liang L; Feng C; Xu H; Wang Z; Liu W; Pu L; Chen Z; Chen G; Wang X
    Oncol Res; 2023; 31(4):481-493. PubMed ID: 37415741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting MAGI2-AS3-modulated Akt-dependent ATP-binding cassette transporters as a possible strategy to reverse temozolomide resistance in temozolomide-resistant glioblastoma cells.
    Chen Z; Zhou J; Liu Y; Ni H; Zhou B
    Drug Dev Res; 2023 Nov; 84(7):1482-1495. PubMed ID: 37551766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.